Five private equity firms, including Apollo Global Management and CVC Capital Partners, are among the bidders for Perrigo's prescription drug unit, according to Bloomberg.
Perrigo announced last year that it wants to sell off its Generic Rx unit to better focus on its consumer business. The unit could sell for more than $2.5 billion, according to people familiar with the matter cited by Bloomberg.
Carlyle Group, Altaris Capital Partners and Cerberus Capital Management also advanced to the next round of bidding for the unit.
Apollo has been increasingly interested in healthcare assets, having purchased Brentwood, Tenn.-based LifePoint Health for $5.6 billion late last year.
Read the full report here.